Performance

Most sites tell you they're fast. We show you.

Live operational performance across the Stryde network. No NDA, no sales call, no cherry-picking. The same numbers our own leadership reviews every Monday.

Updated weekly Reviewed by our Quality lead before every publish · Current metrics available same-day by email
6.5 weeks
Median study startup
Stryde6.5 wks
University sites~10 wks
Cancer centers~24 wks
Site selection to first patient screened, trailing 12 months. Comparators: median activation for industry-sponsored trials at a university site (69 days, about 10 weeks)1 and median across 61 academic cancer centers (167 days, about 24 weeks)2. Need it faster? Depending on sponsor needs and document readiness, we can activate a site in as little as two weeks.
82%
Studies at or ahead of enrollment plan
Stryde82%
Industry~50%
Share of currently enrolling studies meeting or beating the sponsor's enrollment plan. Industry: Tufts CSDD found 37% of sites under-enroll and 11% never enroll a single subject, leaving roughly half at or above target4. Nearly 80% of trials miss their original enrollment timeline5.
31 hrs
Median feasibility response time
Stryde31 hrs
Business hours from request received to preliminary feasibility delivered, trailing 90 days. No published industry benchmark exists for feasibility turnaround, so we won't invent one. That is exactly why we publish ours, backed by our 48-hour guarantee.
94/100
Composite quality score
Windows96.2%
Query rate2.1%
Network average across visit window adherence (target above 90%), data query rate (target under 5%), safety reporting timeliness (100%), and regulatory document currency (100%).
41%
Diverse participant enrollment
Stryde41%
Industry~25%
Participants from racial and ethnic minority groups, network aggregate, trailing 12 months. Industry: about 25% of global trial participants are people of color5. Drawn from 1.5M+ patients across 100+ specialty clinics.

How these numbers are made (and what we won't show you)

Every metric is computed from our clinical trial management system and published as a weekly snapshot after review by our Quality lead. Nothing is hand-typed into this page.

You will never see sponsor names, study identifiers, or per-study data here. Every figure aggregates a minimum of three studies, because our confidentiality obligations to sponsors matter as much as our transparency to you. If a metric would expose a single study, we suppress it for that period and say so.

Benchmark sources

1. Activating clinical trials: a process improvement approach, University of South Florida — median 69 days for industry-sponsored trial activation. pmc.ncbi.nlm.nih.gov/articles/PMC4765218

2. AACI 2018 benchmarking survey / JCO Oncology Practice — median activation of 167 days across 61 cancer centers. ascopubs.org/doi/10.1200/OP.20.00501

3. Advarra, The State of Clinical Trial Activation at Sites — 80% of investigative sites report activation within 60 days. advarra.com

4. Tufts Center for the Study of Drug Development, as reported in Applied Clinical Trials — 37% of sites under-enroll; 11% enroll zero subjects.

5. Applied Clinical Trials — ~80% of trials miss initial enrollment targets and timelines; ~25% of global trial participants are people of color. appliedclinicaltrialsonline.com

Want this quarter's actual numbers today?

Until the live board ships, sponsors can request current metrics by email and receive them the same day, human-sent.

Request current metrics